ACRS - Aclaris Therapeutics Inc.

-

$undefined

N/A

(N/A)

Aclaris Therapeutics Inc. NasdaqGS:ACRS Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Location: 701 Lee Road, Wayne, PA, 19087, United States | Website: https://www.aclaristx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

55.26M

Cash

105.3M

Avg Qtr Burn

-3.079M

Short % of Float

6.81%

Insider Ownership

2.66%

Institutional Own.

88.26%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Bosakitug (ATI-045) Details
Atopic dermatitis

Big Mover™

Susp. Mover™

Phase 2b

Data readout

ATI-1777 (JAK 1/3 inhibitor) Details
Atopic dermatitis, Skin disease/disorder

Phase 2b

Update

Bosakitug (ATI-045) Details
Asthma, Chronic rhinosinusitis with nasal polyps

Big Mover™

Susp. Mover™

Phase 2

Data readout

ATI-2138 Details
Skin disease/disorder, Atopic dermatitis

Big Mover™

Susp. Mover™

Phase 2a

Data readout

Phase 2a

Update

ATI-2138 (ITK/JAK3 inhibitor) Details
Autoimmune disease, Ulcerative colitis

Phase 2a

Initiation

ATI-052 Details
no known indication

Phase 1

Initiation

ATI-2231 (MK2 inhibitor) Details
Solid tumor/s, Cancer, Pancreatic cancer, Metastatic breast cancer

Phase 1a

Update

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued